MetrioPharm Press Releases
-
MetrioPharm Achieves 50% of Target Patients Randomized in MP1032 Phase II Clinical Trial
MetrioPharm AG, today announced that more than 50% of patients with moderate-to-severe psoriasis (PASI entry score 10-20) have been randomized in the company’s ongoing Phase II clinical trial.
-
MetrioPharm Presents Clinical Phase IIa Psoriasis Study Data at the 5th WPPAC in Stockholm
MetrioPharm AG announced that clinical Phase IIa data obtained from patients with moderate to severe plaque psoriasis will be presented at the 5th World Psoriasis & Psoriatic Arthritis Conference (WPPAC) in Stockholm.
-
Data Presentation on the Mechanism of Action of MP1032
MetrioPharm Announces Data Presentation on the Mechanism of Action of MP1032 at the 19th SFRRI Meeting in Lisbon
-
MetrioPharm announces first patient dosed in a clinical phase II trial for MP1032 for the treatment of moderate-to-severe chronic plaque psoriasis
Zurich, March 07, 2018. MetrioPharm AG announces the first dosing of the first patient in its phase II clinical trial MP1032-CT04 on March 06, 2018.
-
MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032 to South Korea
Zurich, September 07, 2017. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in South Korea.
-
MetrioPharm AG Announces Positive Top Line Results from a Phase IIa Study
Zurich, March 14, 2017. Based on these positive results, MetrioPharm plans to move its MP1032 program forward into a phase IIb study in moderate-to-severe psoriasis.
-
MetrioPharm AG Expands Patent Protection to Japan
Zurich, February 14, 2017. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in Japan.
-
Recruiting of MP1032’s Phase IIa trial in psoriasis successfully completed
MetrioPharm AG announces that dosing of the last patient in the clinical phase IIa trial MP1032-CT02 was started on October 20, 2016.
-
MetrioPharm AG Expands Patent Protection for its Lead Compound MP1032
MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries.
-
MetrioPharm AG reinforces its Management and Board for Further Growth
MetrioPharm AG announces that Dr. Sylvie Grégoire has been elected as the new Executive President of MetrioPharm's Board of Directors at the company's 10th Annual General Meeting.